Loading clinical trials...

Development and Clinical Application of a Novel Imaging Grading System for Pheochromocytoma and Paraganglioma (PPGL) | Clinical Trials | Clareo Health

COMPLETED

Development and Clinical Application of a Novel Imaging Grading System for Pheochromocytoma and Paraganglioma (PPGL)

NCT07412158•Peking University First Hospital

View on ClinicalTrials.gov

Summary

This study aims to develop and preliminarily validate an anatomy-morphological risk grading system (IUPU-PPGL Grading) based on preoperative imaging 3D reconstruction, in order to quantitatively assess surgical complexity and perioperative safety in PPGL patients, and to evaluate the value of this grading system for formulating individualized surgical strategies.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•① Patients who underwent curative surgical resection (including laparoscopic, robot-assisted, or open surgery) at our hospital within the study period;
•* Postoperative pathological confirmation of PPGL;
•* Availability of complete preoperative imaging data; ④ Availability of complete perioperative clinical data, including anesthesia records, surgical records, and postoperative hospitalization information; ⑤ Age ≥ 18 years.

Exclusion Criteria

•① Lack of key imaging data or poor image quality that could not meet evaluation requirements;
•* Requirement for concurrent complex surgery for other diseases, making it difficult to independently assess perioperative indicators; ③ History of biopsy only, exploratory surgery, or presence of recurrence, bilateral, or multifocal lesions, preventing independent evaluation; ④ Primary tumors located in special sites (e.g., pelvic, bladder, spermatic cord, or other rare extra-adrenal locations), leading to incomparable surgical approaches and perioperative outcomes.

Locations (1)

Department of Urology, Peking University First Hospital, Beijing, 100034

Beijing, China

Key Dates

Start Date

January 1, 2017

Primary Completion Date

December 1, 2025

Completion Date

December 1, 2025

Last Updated

February 17, 2026

Enrollment

500

ACTUAL participants

Conditions

Risk Grading SystemPheochromocytoma and Paraganglioma (PPGL)Quantitative Assessment

Interventions

observational diagnostic model development

OTHER